Sphere Fluidics launches Cyto-CellectPLUS to accelerate cell line development workflows

Published: 4-Jun-2024

Next-generation assay provides a rapid and cost-effective solution to quantify IgG production in single cells

Sphere Fluidics, a provider of microfluidics-based solutions for single-cell analysis and isolation, has launched Cyto-CellectPLUS.

The novel assay provides a streamlined method to ensure antibody production in single cells. 

It works by rapidly detecting secreted human IgG, enabling the identification and selection of cells with the highest productivity for more efficient cell line development. 

FRET assays for cell line development optimisation

Cyto-CellectPLUS is a robust Fluorescence Resonance Energy Transfer (FRET) assay that enables researchers to quantify IgG productivity. 

Expanding on Sphere Fluidics’ original Cyto-Cellect Human IgG kappa (IgGκ) Detection Kit, Cyto-CellectPLUS now detects both the IgG kappa (κ) and lambda (λ) light chains to support a broader range of projects. 

The assay is fully compatible with existing Cyto-Mine functionality, including single cell dispensing into 96-well and 384-well plates, allowing it to integrate into customers’ existing cell line development workflows. 

It also conforms to relevant regulatory requirements by being animal-origin-free.


Cyto-Mine for automated single cell screening

Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification in one bench-top system. 

Underpinned by the company’s microfluidic picodroplet technology, it can automatically screen up to 40 million cells in a matter of hours, compared with the 10,000 typically achieved using multi-step manual techniques. 

This accelerated throughput is already widely recognised across a variety of research areas, including antibody discovery, cell line development, cell engineering and synthetic biology. 

The platform also facilitates rapid, high-throughput single cell manipulation and analysis across an expanding range of emerging research areas, including precision genome editing and cell therapy.

Director of Cell and Molecular Biology, Sphere Fluidics Maryam Ahmadi said: “By facilitating the detection of both light chains of IgG, this assay builds on our original Cyto-Cellect kit, providing a complete solution to enable researchers to identify and select cells with the highest productivity for downstream research.”


You may also like